Abstract 17096: Assessing the Prevalence of Atherogenic Dyslipidemia in EURIKA Patients
Introduction: Atherogenic dyslipidemia (AD), a condition identified by high triglyceride (TG) and/or low high-density lipoprotein cholesterol (HDL-C) levels, is associated with worse cardiovascular disease (CVD) outcomes.
Methods: We used data from the European Study on Cardiovascular Risk Prevention and Management in Usual Daily Practice (EURIKA, NCT00882336) to analyze the prevalence of AD according to patients’ CVD risk levels, determined using AHA/ACC (risk of atherosclerotic cardiovascular disease [ASCVD]; Table 1) and European (systematic coronary risk evaluation-HDL [SCORE-HDL]; Table 2) criteria. Patients in EURIKA were free from CVD but had at least one CVD risk factor (N=7641). AD was defined as TG ≥200 mg/dL and/or HDL-C <40 mg/dL in men and <50 mg/dL in women.
Results: A large proportion of patients from EURIKA have high TG and/or low HDL-C levels characteristic of AD (Tables). Using AHA/ACC criteria to assess patients not receiving statin treatment and at high risk for CVD (type 2 diabetes [T2DM]; ASCVD risk ≥7.5%), the proportions with high TG, low HDL-C or both were 28.9%, 31.7% and 16.3%, respectively; for patients at low risk (without T2DM; ASCVD risk <7.5%), the respective proportions were 11.6%, 17.9% and 4.9%. Similarly, a higher proportion of patients defined as being at high risk by European criteria (T2DM, or SCORE-HDL ≥5%) had signs of AD than those at low risk (without T2DM, or SCORE-HDL <5%). Prevalence of AD was greater in patients with T2DM, but similar in those receiving statins and those who were not.
Conclusions: Many patients at high risk of CVD also have signs of AD and may benefit from more intensive preventive measures.
Author Disclosures: J.P. Halcox: Research Grant; Modest; AstraZeneca. Speakers Bureau; Modest; MSD, Abbott, Astra Zeneca. Consultant/Advisory Board; Modest; AstraZeneca, MSD, Abbott. C. Roy: None. K.M. Henriksson: Employment; Significant; AstraZeneca.
- © 2015 by American Heart Association, Inc.